The positive correlation between PDW and the log-transformed PRL in our study suggests that hyperprolactinemia in OLZ-treated patients might be associated with the increased risk of thromboembolic events because PDW increases during platelet activation (65). This evidence concerns the gene PRL and hyperprolactinemia.